REVIEW OF MATRIX TYPE TRANSDERMAL PATCHES OF BENAZEPRIL HYDROCHLORIDE

Transdermal drug delivery systems are defined as self-contained, discrete dosage forms which, when applied to the intact skin, deliver the drug(s), through the skin, at a controlled rate to the circulation (Monkhouse and Huq, 1988). FDA approved the primary skin patch products in 1981. These delivery systems provided the controlled systemic absorption of scopolamine for the prevention of sickness (TransdermScop, ALZA Corp.) and nitroglycerine for the prevention of angina related to arterial blood vessel disease (Transderm‐Nitro). Over the last twenty years, over 35 transdermal products are approved generating sales of $3.2 billion in 2002, which is predicted to rise to $4.5 billion in 2008. More recently, such dosage forms are developed and/or modified so as to reinforce the actuation of drug diffusion (thermodynamic activity) and/or increase the permeability of the skin. These approaches include the employment of penetration enhancers, supersaturated systems, prodrugs, liposomes and other vesicles (Bhavna yadav et al., 2011). KEYWORDS- Transdermal Patches, Benazepril Hydrochloride, Eudragit L100